A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pronk, L C, Vasey, P, Sparreboom, A, Reigner, B, Planting, A S Th, Gordon, R J, Osterwalder, B, Verweij, J, Twelves, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374547/
https://www.ncbi.nlm.nih.gov/pubmed/10883663
http://dx.doi.org/10.1054/bjoc.2000.1160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374547/
https://www.ncbi.nlm.nih.gov/pubmed/10883663
http://dx.doi.org/10.1054/bjoc.2000.1160

Ejemplares similares